Acorda Therapeutics (NASDAQ:ACOR) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Friday.
Several other equities analysts have also issued reports on the company. Oppenheimer reiterated a “hold” rating on shares of Acorda Therapeutics in a research note on Tuesday, March 19th. Zacks Investment Research lowered Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, March 18th. ValuEngine lowered Acorda Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, February 15th. Cantor Fitzgerald restated a “hold” rating and set a $20.00 price target on shares of Acorda Therapeutics in a research note on Friday, February 15th. Finally, HC Wainwright set a $33.00 price target on Acorda Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 23rd. Five equities research analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $22.56.
ACOR opened at $13.13 on Friday. Acorda Therapeutics has a 1 year low of $12.55 and a 1 year high of $36.35. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.56 and a current ratio of 3.77. The stock has a market capitalization of $625.42 million, a price-to-earnings ratio of 8.10 and a beta of 1.49.
Acorda Therapeutics (NASDAQ:ACOR) last posted its earnings results on Thursday, February 14th. The biopharmaceutical company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $1.64. Acorda Therapeutics had a return on equity of 12.98% and a net margin of 7.14%. The company had revenue of $69.20 million for the quarter, compared to analyst estimates of $48.12 million. During the same quarter in the previous year, the firm earned $0.61 earnings per share. The firm’s quarterly revenue was down 63.3% compared to the same quarter last year. Sell-side analysts predict that Acorda Therapeutics will post -3.86 EPS for the current fiscal year.
In other news, major shareholder Scopia Capital Management Lp sold 52,891 shares of the business’s stock in a transaction dated Friday, December 28th. The stock was sold at an average price of $14.99, for a total transaction of $792,836.09. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 635,194 shares of company stock worth $10,303,006 in the last 90 days. Insiders own 7.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of ACOR. Bank of Montreal Can boosted its position in Acorda Therapeutics by 100.8% in the fourth quarter. Bank of Montreal Can now owns 2,116 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 1,062 shares during the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in Acorda Therapeutics in the fourth quarter valued at approximately $44,000. NumerixS Investment Technologies Inc purchased a new stake in Acorda Therapeutics in the fourth quarter valued at approximately $77,000. Pacer Advisors Inc. purchased a new stake in Acorda Therapeutics in the third quarter valued at approximately $110,000. Finally, Schroder Investment Management Group purchased a new stake in Acorda Therapeutics in the third quarter valued at approximately $112,000.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.
See Also: Bond
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.